-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, the CDE official website shows that the PD-1 monoclonal antibody Balstilimab (Balstilimab), a collaboration between Betta Pharmaceuticals and Agenus, has been approved for clinical use in advanced cervical cancer
.
Bartilimumab is one of the two monoclonal antibody products acquired by Betta Pharmaceuticals from Agenus with a US$15 million down payment + US$20 million shares.
The other is the CTLA-4 monoclonal antibody Zalifrelimab
.
Through this transaction, Betta has obtained the exclusive development and commercialization rights of these two products in China (including Hong Kong, Macau and Taiwan) for single use or in combination with other drugs to treat all indications except intravesical administration